Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes
Get Alerts ALNY Hot Sheet
Rating Summary:
24 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Yesterday, November 11, Alnylam Pharmaceuticals (NASDAQ: ALNY) and The Medicines Company (NASDAQ: MDCO) reported ALN-PCSsc Phase I data during a late-breaker session at the American Heart Association (AHA) meeting held in Orlando.
The additional data in healthy volunteers with elevated LDL-C further supported the potential for a bi-annual dosing regimen with a least square mean (LSM) percentage reduction of LDL-C of 47%, 180 days following a 300 mg single administration of ALN-PCSsc. The therapy continues to be well tolerated and achieved LDL-C lowering competitive with currently approved monoclonal antibodies (MAbs).
FBR Capial analyst, Christopher James, believes the potential for bi-annual dosing, the potent lowering of LDLC, and the safe profile support a potential best-in-class profile for the treatment of hypercholesterolemia.
No change to Outperform rating or $180PT.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $104.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $170 at Morgan Stanley
- Westamerica Bancorp (WABC) PT Lowered to $50 at Piper Sandler
- American International Group (AIG) PT Raised to $89 at Piper Sandler
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!